Tetraphase Pharmaceuticals Enters into Exclusive Development and Commercialization Agreement with Everest Medicines for Eravacycline in China
20. Februar 2018 16:01 ET
|
Tetraphase Pharmaceuticals, Inc.
WATERTOWN, Mass., Feb. 20, 2018 (GLOBE NEWSWIRE) --
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics...
Tetraphase Announces Top-Line Results from IGNITE3 Phase 3 Clinical Trial of Eravacycline in Complicated Urinary Tract Infections (cUTI)
13. Februar 2018 16:01 ET
|
Tetraphase Pharmaceuticals, Inc.
̶ Eravacycline Did Not Achieve Co-Primary Endpoints in cUTI Trial ̶ ̶ Company Continues to Prepare for Commercialization of Eravacycline as a Treatment for cIAI in the U.S. and Europe,...
Tetraphase Pharmaceuticals Appoints Larry Tsai, M.D. to Chief Medical Officer
02. Januar 2018 16:35 ET
|
Tetraphase Pharmaceuticals, Inc.
WATERTOWN, Mass., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening...
Tetraphase Pharmaceuticals Announces Submission of New Drug Application to FDA for Eravacycline for the Treatment of Complicated Intra-Abdominal Infections (cIAI)
02. Januar 2018 16:30 ET
|
Tetraphase Pharmaceuticals, Inc.
WATERTOWN, Mass., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening...
Tetraphase Pharmaceuticals Added to NASDAQ Biotechnology Index
15. Dezember 2017 08:00 ET
|
Tetraphase Pharmaceuticals, Inc.
WATERTOWN, Mass., Dec. 15, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening...
Tetraphase Pharmaceuticals to Present at BMO Prescriptions for Success in Healthcare Conference 2017
06. Dezember 2017 08:00 ET
|
Tetraphase Pharmaceuticals, Inc.
WATERTOWN, Mass., Dec. 06, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening...
Tetraphase Pharmaceuticals to Present at Upcoming Investor Conferences
06. November 2017 08:30 ET
|
Tetraphase Pharmaceuticals, Inc.
WATERTOWN, Mass., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening...
Tetraphase Pharmaceuticals Reports Third Quarter 2017 Financial Results and Highlights Recent Clinical and Corporate Achievements
02. November 2017 08:00 ET
|
Tetraphase Pharmaceuticals, Inc.
WATERTOWN, Mass., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing novel antibiotics to treat life-threatening...
Tetraphase Pharmaceuticals Appoints Kam Unninayar as Chief Financial Officer
16. Oktober 2017 09:00 ET
|
Tetraphase Pharmaceuticals, Inc.
WATERTOWN, Mass., Oct. 16, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening...
Tetraphase Pharmaceuticals Presents Clinical Data from Oral Eravacycline Development Program at IDWeek 2017
04. Oktober 2017 08:00 ET
|
Tetraphase Pharmaceuticals
WATERTOWN, Mass., Oct. 04, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening...